Nyxoah's Stock Rebounds 12% in Session After a 52% Annual Decline
The stock of the Belgian medtech company specializing in sleep apnea treatment has shown a significant rebound this Tuesday, trading at 2.70 euros during the session. This surge comes amidst a prolonged downturn, with the stock having lost over 52% over the past year and 41% in the last three months.
At midday, Nyxoah is trading at 2.70 euros, up 12.73% from the previous close of 2.40 euros. However, this movement is part of a negative underlying dynamic: over the past seven days, the stock has still lost 11.18%. The 50-day moving average, at 3.73 euros, and the 200-day average, at 4.87 euros, remain well above the current price, confirming the predominance of the downward trend. The RSI, at 21, indicates a marked oversold zone, which could mechanically explain this temporary rebound after several sessions of decline. The stock is trading in the lower part of the Bollinger Bands, close to the lower limit set at 2.35 euros, while the upper limit is at 4.04 euros. The nearest technical support, at 2.66 euros, has been tested and seems to currently hold back the selling pressure. The major resistance, identified at 4.00 euros, remains far from the current price, illustrating the significant distance the stock must cover to return to levels more in line with its valuation at the end of 2025.
Upcoming Financial Calendar and Market Context
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The next key date in the company's financial calendar is the publication of the first quarter 2026 results, scheduled for May 12. This event could be a crucial catalyst for the stock's trajectory, in a context where monthly volatility stands at 18.19%. This will be followed by the general assembly scheduled for June 10, and then the semi-annual results on August 5. The negative beta of -0.28 indicates a generally decoupled evolution from the major European indices, which are showing a positive trend this Tuesday: the CAC 40 is up 0.60% in session at 8,285.33 points, while the DAX has advanced 0.94% to 23,964.87 points. The S&P 500 closed up 1.02% at 6,886.24 points. Nyxoah's progress today thus does not seem directly linked to the direction of the markets but rather to a dynamic specific to the stock, after a prolonged period of decline that has brought the price to floor levels.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 14 millions d'euros
Quarterly revenue: 14 millions d'euros
Revenue growth: 484,4 %
Net income: -48,9 millions d'euros
Guidance from the release
nous sommes confiants dans le fait que l'environnement de remboursement actuel soutient l'accélération de notre croissance du chiffre d'affaires aux États-Unis
Risks mentioned
Baisse de la marge brute à 59 % au S1 2026 due à des problèmes de rendement de production au T1 et à un mix de revenus américain plus important
Augmentation des charges de vente, générales et administratives liée au déploiement commercial aux États-Unis
Perte opérationnelle en hausse à 41,1 M€ au S1 2026 contre 40,5 M€ au S1 2025
Opportunities identified
Financement de 110 millions de dollars sécurisé au T2 2026 pour financer la croissance commerciale
Taux d'approbation de 100 % sur les demandes d'autorisation préalable pour les patients commerciaux et WISeR
Code Medicare C-code 8011 dédié à Genio, clarifiant le paysage de remboursement
Outlook / guidance
Expected revenue: 38 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
